Lisa Haile

Lisa Haile

DLA Piper

Contact  |  View Bio  |  RSS

Latest Publications

Share:

Patentability of isolated nucleic acid: US vs. Australia

Patents directed to genetic material have been t­­­­he subject of significant public discourse and legal challenge worldwide, leading to a divergence of governing law between jurisdictions and heightened industry uncertainty...more

12/22/2014 - Ambry AMP v Myriad Australia Genetic Materials Guidance Update Mayo v. Prometheus Patent-Eligible Subject Matter Patents USPTO

Intellectual Property and Technology News - December 2014 (Global)

In This Issue: - Fundamental Reform Ahead For European Patent Law - Patentability of Isolated Nucleic Acid - Patent Reform – Is It Working? - Right To Privacy In Japan - Supreme Court Corner - The FTC...more

12/22/2014 - Ambry AMP v Myriad DNA EU FTC FTC v Actavis Genetic Materials Guidance Update Japan Patent Reform Patent-Eligible Subject Matter Patents Popular Right to Privacy SCOTUS USPTO

Intellectual Property and Technology News | Issue 4, Q3 2013 (Global)

In This Issue: - IPT INSIGHTS - INTELLECTUAL PROPERTY AND SPORT – A WINNING COMBINATION... - THE CJEU GOES TO THE MOVIES: REFLECTIONS ON FILM COPYRIGHT FROM AUSTRIA, THE NETHERLANDS AND THE UK - CLOUD...more

9/6/2013 - AMP v Myriad Biotechnology CJEU Cloud Computing Copyright Data Protection DNA Genetic Materials Human Genes Patent-Eligible Subject Matter Pharmaceutical ROI SCOTUS Technology

The future of DNA patents

The US Supreme Court has ruled that certain patent claims owned by Myriad Genetics, the US biotech company that holds the patents covering a test for breast cancer related genes (BRCA1 and BRCA2), are invalid as products of...more

9/5/2013 - AMP v Myriad DNA Genetic Materials Human Genes Patent-Eligible Subject Matter Patents SCOTUS

What Supreme Court’s Myriad decision means for biopharma companies

On June 13, 2013, the US Supreme Court ruled that certain patent claims owned by Myriad Genetics, the US biotech company that holds the patents covering a test for a breast-cancer related genes (BRCA1 and BRCA2), are invalid...more

6/14/2013 - AMP v Myriad Biotechnology DNA Human Genes Myriad Patent-Eligible Subject Matter Patents SCOTUS

5 Results
|
View per page
Page: of 1

All the intelligence you need, in one easy email:

Great! Your first step to building an email digest of JD Supra authors and topics. Log in with LinkedIn so we can start sending your digest...

Sign up for your custom alerts now, using LinkedIn ›

* With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name.
×